Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
We demonstrate the application of ENLIGHT-DP, a transcriptome-based biomarker for accurate prediction of treatment of LUAD with ICI and platinum-based chemotherapy, outperforming PD-L1 and TMB, and relying solely on accessible H&E scanned slides. Further studies on different tumor types, ICI monotherapy and bigger NSCLC cohorts are warranted.
Authors
- Hovav Nechushtan (ORCID: https://orcid.org/0000-0003-3411-800X)
- Yaron Kinar (ORCID: https://orcid.org/0009-0002-1013-1330)
- Eli Pikarsky (ORCID: https://orcid.org/0000-0003-4186-7105)
- Aron Popovtzer (ORCID: https://orcid.org/0000-0003-4428-9232)
- Tuvik Beker (ORCID: https://orcid.org/0009-0009-1433-489X)
- Ranit Aharonov
- Yakir Rottenberg (ORCID: https://orcid.org/0000-0002-5838-8867)
- Gal Dinstag (ORCID: https://orcid.org/0009-0004-3942-9629)
- Johnathan Arnon (ORCID: https://orcid.org/0000-0002-5688-5712)
- Anna Elia
- Omer Tirosh (ORCID: https://orcid.org/0000-0001-8139-9866)
- Philip Blumenfeld (ORCID: https://orcid.org/0000-0003-4672-6862)
- Leon Gugel
- Michael Tabi
- Tzivia Gottlieb
Institutions
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-010132
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09